Drugs / HRG2010
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06976346 | Sep → Oct 2021 | Parkinson disease | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06614153 | May 2023 → Jan 2024 | Parkinson disease | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06596876 | Nov 2024 → Oct 2025 | Parkinson disease | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRG2010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06596876 ↗ |
| Route | Oral | “administered orally” NCT06596876 ↗ |